Article (Scientific journals)
Risankizumab-Aggravated Crusted Scabies in a Patient with Down Syndrome
SENTERRE, Yseult; Jouret, Gaëlle; Collins, Patrick et al.
2020In Dermatology and Therapy, 10 (4), p. 829-834
Peer Reviewed verified by ORBi
 

Files


Full Text
Senterre2020_Article_Risankizumab-AggravatedCrusted.pdf
Publisher postprint (824.39 kB)
Download

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.


All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Crusted scabies; Cutaneous parasitic infections; Down syndrome; Immunosuppression; Interleukin-17; Interleukin-23; Psoriasis; Risankizumab; C reactive protein; Article; Sarcoptes scabiei
Abstract :
[en] Risankizumab, an interleukin (IL)-23 antagonist, is a highly effective treatment for moderate to severe psoriasis. Crusted scabies (CS) is a rare and severe form of scabies, occurring mainly in immunosuppressed patients and/or neurologically or mentally ill patients. A young girl with Down syndrome was diagnosed with a hyperkeratotic form of psoriasis. As treatment with topical dermocorticosteroids, UVB-phototherapy and acitretin for 6 weeks did not improve the lesions, two injections of risankizumab were administered. Following these injections, the lesions became rapidly even more severely crusted, and new lesions appeared on the extremities and the face of the patient. There was histological evidence of a high charge of scabies, leading to a diagnosis of CS. The patient was hospitalized and successfully treated by local permethrine and systemic ivermectine. This case suggests that even though anti-IL23 antagonists display an excellent overall safety profile, a particular caution for infections should still be respected in patients with underlying risk factors. © 2020, The Author(s).
Disciplines :
Dermatology
Author, co-author :
SENTERRE, Yseult ;  Centre Hospitalier Universitaire de Liège - CHU > Autres Services Médicaux > Service de dermatologie
Jouret, Gaëlle ;  Centre Hospitalier Universitaire de Liège - CHU > Autres Services Médicaux > Service de dermatologie
Collins, Patrick ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Nikkels, Arjen ;  Université de Liège - ULiège > Département des sciences cliniques > Dermatologie
Language :
English
Title :
Risankizumab-Aggravated Crusted Scabies in a Patient with Down Syndrome
Publication date :
2020
Journal title :
Dermatology and Therapy
ISSN :
2193-8210
eISSN :
2190-9172
Publisher :
Springer, Heidelberg, Germany
Volume :
10
Issue :
4
Pages :
829-834
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 04 November 2021

Statistics


Number of views
70 (3 by ULiège)
Number of downloads
73 (3 by ULiège)

Scopus citations®
 
4
Scopus citations®
without self-citations
4
OpenCitations
 
5

Bibliography


Similar publications



Contact ORBi